Helicopter crashes during power line work, killing two on board and prompting river closure as investigation begins.
Novartis' drug ianalumab meets Phase III endpoints in Sjögren's disease trials, potentially offering the first targeted therapy for this chronic autoimmune disorder.
Helicopter crashes during power line work, killing two on board and prompting river closure as investigation begins.
Novartis' drug ianalumab meets Phase III endpoints in Sjögren's disease trials, potentially offering the first targeted therapy for this chronic autoimmune disorder.